MiniMed Secures Canadian License for Simplera Sync Sensor and Type 2 Indication
Health Canada licensed new MiniMed 780G software integrating the Simplera Sync disposable sensor and extending Type 2 diabetes indication for adults 18+ with Fiasp compatibility. Its adaptive algorithm with Meal Detection and SmartGuard technologies adjusts glucose every 5 minutes to help users maintain over 80% time in range.
1. Canadian Regulatory Approval
Health Canada has licensed updated MiniMed 780G software to include the Simplera Sync sensor and grant Type 2 diabetes indication for adults aged 18 and older. The approval also covers compatibility with Fiasp rapid-acting insulin, expanding the system’s use beyond Type 1 diabetes in Canada.
2. Simplera Sync Sensor Features
The Simplera Sync sensor is a disposable, all-in-one device with a two-step insertion process that omits overtape and fingersticks when used with SmartGuard. Its design aims to enhance comfort and reduce daily maintenance compared with existing continuous glucose monitors.
3. Clinical Performance and Capabilities
The MiniMed 780G system’s adaptive algorithm automatically adjusts insulin every five minutes based on glucose trends, leveraging Meal Detection technology to respond to rises without user input. Combined with the world’s first seven-day infusion set, the system has demonstrated over 80% time in range under optimal settings.
4. Commercial Outlook
The Simplera Sync sensor is scheduled to launch in Canada later this year, positioning MiniMed to capture additional adult Type 2 diabetes market share. Broader indication and enhanced user convenience may drive incremental revenue growth in the Canadian diabetes care segment.